Company Overview
Snapshot
Founded in December 2011 by Immanuel Lerner, Anwar Rayan, and Amit Michaeli, Pepticom operates with 11–50 employees. The company has raised $14.2 million across 4 funding rounds from 3 investors. In January 2025, Pepticom successfully completed a Series A1 funding round, with.
Business overview
Pepticom is a biotechnology company that leverages artificial intelligence to enhance peptide drug discovery. Its proprietary algorithmic platform integrates economic and molecular mechanics principles to generate a broad spectrum of active molecules, aiming to increase success rates while reducing the time and cost associated with traditional lab-based discovery methods. The company's technology is capable of designing innovative peptides at atomic resolution, including linear, helical, and cyclic peptides, and can incorporate D and non-natural amino acids. Pepticom serves the pharmaceutical and biotechnology industries, focusing on areas such as immunology, oncology, and metabolic diseases, with a presence in markets including Japan, Europe, China, and the United States.
Strategic signal
In March 2021, Pepticom established a spin-off company, PeptiCov, specifically to develop treatments for the SARS-CoV-2 virus. This strategic move demonstrates Pepticom's agility in responding to global health crises and its ability to leverage its AI-driven peptide discovery platform for urgent medical needs, signaling potential for rapid product development and market responsiveness to investors.
Log in to access full profile ›Company Intelligence Q&A
- What was a significant recent funding event for Pepticom?
- In January 2025, Pepticom successfully completed its Series A1 funding round. The Chartered Group was a lead investor in this round.
- What is Pepticom's core technology?
- Pepticom utilizes an AI-driven algorithmic platform that combines economic and molecular mechanics principles to design novel peptide drug candidates at atomic resolution, streamlining the drug discovery process.
- What strategic initiative did Pepticom undertake in response to the COVID-19 pandemic?
- In March 2021, Pepticom established a spin-off company named PeptiCov, dedicated to developing treatments for the SARS-CoV-2 virus responsible for the COVID-19 outbreak.
- When was Pepticom founded and by whom?
- Pepticom was founded in December 2011 by Immanuel Lerner, Anwar Rayan, and Amit Michaeli.